Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Infantile Hemangioma, Very Low Birth Weight Infants

In brief

The purpose of this trial is to see if a topical beta blocker is effective in preventing the proliferation of infantile hemangioma.

Key facts

Study ID

NCT01434849

Run by

Alice K. Gong

People needed

26

Starts

2012-07-01

Expected to finish

2016-04-01

Last updated by the study team

2016-11-15

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Babies admitted to NICU or seen in follow clinic that have a diagnosis of hemangioma that is verified by Principal Investigator (PI) or Co-Principal Investigators.

You may not qualify if…

• Babies with PHACES (Posterior fossa, Hemangioma, Arterial lesions, Cardiac abnormalities, Eye abnormalities) syndrome
• Babies with cardiac conditions that may predispose to heart block
• Babies with persistent hypoglycemia
• Babies on medications that may interact with beta blockers
• Babies who are hemodynamically unstable and are requiring pressors to maintain blood pressure
• Babies who are on systemic corticosteroid therapy

Where it is running

• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.